The DOI matches its Crossref record; 234 of the 234 references it cites were found in a registry or an index.
Blood Brain Barrier: A Challenge for Effectual Therapy of Brain Tumors
Open accessAbstract
Brain tumors are one of the most formidable diseases of mankind. They have only a fair to poor prognosis and high relapse rate. One of the major causes of extreme difficulty in brain tumor treatment is the presence of blood brain barrier (BBB). BBB comprises different molecular components and transport systems, which in turn create efflux machinery or hindrance for the entry of several drugs in brain. Thus, along with the conventional techniques, successful modification of drug delivery and novel therapeutic strategies are needed to overcome this obstacle for treatment of brain tumors. In this review, we have elucidated some critical insights into the composition and function of BBB and along with it we have discussed the effective methods for delivery of drugs to the brain and therapeutic strategies overcoming the barrier.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–234 of 234
The molecular biology of renal organic anion and organic cation transporters
Sweet, D. H., & Pritchard, J. B. (1999) · Cell Biochemistry and Biophysics · doi:10.1007/bf02738157 · Cited by 75
Mohrmann, K., van Eijndhoven, M. A. J., Schinkel, A. H., & Schellens, J. H. M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1004-5 · Cited by 71
Theranostic GO‐Based Nanohybrid for Tumor Induced Imaging and Potential Combinational Tumor Therapy
Qin, S., Feng, J. X., Rong, L., Jia, H., Chen, S., Liu, X., Luo, G., Zhuo, R., & Zhang, X. (2013) · Small · doi:10.1002/smll.201301613 · Cited by 71
Mani, R. S., Hammond, J. R., Marjan, J. M. J., Graham, K., Young, J. D., Baldwin, S. A., & Cass, C. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30818 · Cited by 70
Pain and the blood–brain barrier: obstacles to drug delivery
Wolka, A. M., Huber, J. D., & Davis, T. P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00100-5 · Cited by 68
Fine, R. L., Chen, J., Balmaceda, C. M., Bruce, J. N., Huang, M., Desai, M., Sisti, M. B., McKhann, G. M., Goodman, R. R., Bertino, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2356 · Cited by 67
OCTN3 is a mammalian peroxisomal membrane carnitine transporter
Lamhonwah, A., Ackerley, C. A., Tilups, A., Edwards, V., Wanders, R. J. A., & Tein, I. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.170 · Cited by 65
Characteristics of sequential targeting of brain glioma for transferrin-modified cisplatin liposome
Lv, Q., Li, L., Han, M. Y., Tang, X.-J., Yao, J.-N., Ying, X., Li, F., & Gao, J.-Q. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.01.025 · Cited by 65
Catanionic solid lipid nanoparticles carrying doxorubicin for inhibiting the growth of U87MG cells
Kuo, Y., & Liang, C.-T. (2011) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2011.02.011 · Cited by 64
Wang, C., Lin, W., Playa, H. C., Sun, S., Cameron, K. S., & Buolamwini, J. K. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.063 · Cited by 62
Study on brain targeting of raltitrexed following intranasal administration in rats
Wang, D., Gao, Y., & Yun, L. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0018-3 · Cited by 62
Wang, Y., Wang, C., Gong, C., Wang, Y., Guo, G. F., Luo, F., & Qian, Z. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.05.015 · Cited by 58
Sanchez‐Covarrubias, L., Slosky, L. M., Thompson, B. J., Zhang, Y., Laracuente, M., DeMarco, K. M., Ronaldson, P. T., & Davis, T. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088516 · Cited by 57
Jain, A., Chashoo, G., Singh, S. K., Saxena, A. K., & Jain, S. (2010) · Journal of Microencapsulation · doi:10.3109/02652048.2010.522257 · Cited by 57
Structural and histochemical features of the avian blood‐brain barrier
Stewart, P. A., & Wiley, M. J. (1981) · The Journal of Comparative Neurology · doi:10.1002/cne.902020203 · Cited by 56
Gene Targeting In Vivo with Pegylated Immunoliposomes
Pardridge, W. M. (2003) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(03)73032-8 · Cited by 53
Modulation of Blood-Brain Barrier Permeability
Rapoport, S. I. (1996) · Journal of drug targeting · doi:10.3109/10611869609015962 · Cited by 53
Expression and localization of claudins-3 and -12 in transformed human brain endothelium
Schrade, A., Sade, H., Couraud, P., Romero, I. A., Weksler, B. B., & Niewoehner, J. (2012) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-9-6 · Cited by 52
Shashoua, V. E., & Hesse, G. W. (1996) · Life Sciences · doi:10.1016/0024-3205(96)00101-4 · Cited by 51
A glial-specific, repressible, adenovirus vector for brain tumor gene therapy.
Chen, J., Bezdek, T., Chang, J., Kherzai, A., Willingham, T., Azzara, M., & Nisen, P. D. (1998) · PubMed · Cited by 43
Nuriya, M., Shinotsuka, T., & Yasui, M. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhs198 · Cited by 43
A novel chemical delivery system for brain targeting
Yoshikawa, T., Sakaeda, T., Sugawara, T., Hirano, K., & Stella, V. J. (1999) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(98)00091-x · Cited by 40
Cancer vaccines and immunotherapies: emerging perspectives
HENDERSON, R., Mossman, S. P., Nairn, N. W., & Cheever, M. A. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.01.082 · Cited by 35
Kang, C., Yuan, X., Zhong, Y., Pu, P., Guo, Y., Albadany, A., Yu, S., Zhang, Z., Li, Y., Chang, J. K., et al. (2009) · Technology in Cancer Research & Treatment · doi:10.1177/153303460900800108 · Cited by 35
Kuo, Y., & Hong, T.-Y. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.02.008 · Cited by 34
Toxin-Based Targeted Therapy for Malignant Brain Tumors
Chandramohan, V., Sampson, J. H., Pastan, I. H., & Bigner, D. D. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/480429 · Cited by 32
Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma
Fenstermaker, R. A., & Ciesielski, M. J. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.881255 · Cited by 31
Multidrug Resistance in Glioblastoma
Leweke, F., Damian, M. S., Schindler, C., et al. (1998) · Pathology - Research and Practice · doi:10.1016/s0344-0338(98)80015-0 · Cited by 29
De, K., Bhowmik, A., Behera, A., Banerjee, I., Ghosh, M. K., & Misra, M. (2012) · Journal of Peptide Science · doi:10.1002/psc.2458 · Cited by 25
Self-citationFiorillo, A., Maggi, G., Greco, N., Migliorati, R., D’Amico, A., De, M. D. B., Sabbatino, M. S., & Buffardi, F. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000013471.53015.52 · Cited by 20
Thomsen, L. B., Lichota, J., Eskehave, T. N., Linemann, T., Mortensen, J. H., du Jardin, K. G., & Moos, T. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112803341842 · Cited by 16
Brain‐to‐Blood Transport of Peptides and the Alcohol Withdrawal Syndrome
Banks, W. A., & Kastin, A. J. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb19812.x · Cited by 15
Critical Analysis of Cancer Therapy using Nanomaterials
Juillerat‐Jeanneret, L. (2003) · Wiley eBooks · doi:10.1002/9783527610419.ntls0066 · Cited by 14
ABC Transporters in Human Disease
Moitra, K. (2012) · Colloquium Series on The Genetic Basis of Human Disease · doi:10.4199/c00055ed1v01y201204gbd001 · Cited by 4
Cited by
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Karri, V., Schuhmacher, M., & Kumar, V. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.09.016 · Cited by 514
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Clinical and molecular aspects of lead toxicity: An update
Mitra, P., Sharma, S., Purohit, P., & Sharma, P. (2017) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2017.1408562 · Cited by 389
Agrawal, M., Ajazuddin, Tripathi, D. K., Saraf, S., Saraf, S., Antimisiaris, S. G., Mourtas, S., Hammarlund-Udenaes, M., & Alexander, A. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.05.019 · Cited by 356
Metadata
- Authors
- Bhowmik, A., Khan, R., & Ghosh, M. K.
- Venue
- BioMed Research International
- Publisher
- Wiley
- Published
- 2015
- Volume
- 2015
- Pages
- 1-20
- ISSN
- 1110-7243 (ISSN-L)
- 2314-6133
- 2314-6141
- OpenAlex
- W2080182688
- Cited by
- 291
- References
- 234
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.